Compare BZ & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | RYTM |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.3B |
| IPO Year | 2021 | 2017 |
| Metric | BZ | RYTM |
|---|---|---|
| Price | $16.75 | $86.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 19 |
| Target Price | $21.76 | ★ $143.94 |
| AVG Volume (30 Days) | ★ 4.2M | 705.8K |
| Earning Date | 11-17-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.42 | $66.07 |
| Revenue Next Year | $12.58 | $79.32 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $74.50 |
| 52 Week High | $22.80 | $122.20 |
| Indicator | BZ | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 28.22 |
| Support Level | $12.95 | $82.43 |
| Resistance Level | $17.47 | $92.51 |
| Average True Range (ATR) | 0.43 | 3.29 |
| MACD | 0.24 | -0.21 |
| Stochastic Oscillator | 96.12 | 10.27 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.